Neuropeptide Y Y1 receptors mediate morphine-induced reductions of natural killer cell activity

Journal of Neuroimmunology

Volumn 177, Issue 1-2, 2006, Pages 18-26

  Saurer, Timothy B ^a   Ijames, Stephanie G ^a   Lysle, Donald T ^a  

^a University of North Carolina at Chapel Hill   (United States)

Author keywords

BIBP3226; Natural killer cell activity; NPY; Nucleus accumbens; Opioid; Spleen

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; CONCANAVALIN A; DOPAMINE 1 RECEPTOR STIMULATING AGENT; LIPOPOLYSACCHARIDE; MORPHINE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE RECEPTOR; NEUROPEPTIDE Y; PEPTIDE YY; ANXIOLYTIC AGENT; ARGININE; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; NARCOTIC AGENT; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y Y1 RECEPTOR; NEUROPEPTIDE Y-Y1 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; LYMPHOCYTE PROLIFERATION; MALE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ADRENERGIC SYSTEM; ANIMAL; CYTOLOGY; DISEASE MODEL; DOWN REGULATION; DRUG INTERACTION; DRUG POTENTIATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOMODULATION; LEWIS RAT; METABOLISM; MORPHINE ADDICTION; NUCLEUS ACCUMBENS; PATHOPHYSIOLOGY; PHYSIOLOGY; SPLEEN;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; ANTI-ANXIETY AGENTS; ARGININE; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG INTERACTIONS; IMMUNE TOLERANCE; KILLER CELLS, NATURAL; MALE; MORPHINE; MORPHINE DEPENDENCE; NARCOTICS; NEUROIMMUNOMODULATION; NEUROPEPTIDE Y; NUCLEUS ACCUMBENS; RATS; RATS, INBRED LEW; RECEPTORS, DOPAMINE D1; RECEPTORS, NEUROPEPTIDE Y; SPLEEN; SYMPATHETIC NERVOUS SYSTEM;

EID: 33746273169     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.05.002     Document Type: Article

References (41)

1. Appel N.M., Kiritsy-Roy J.A., and Van Loon G.R. Mu receptors at discrete hypothalamic and brainstem sites mediate opioid peptide-induced increases in central sympathetic outflow. Brain Res. 378 (1986) 8-20
2. Bayer B.M., Hernandez M., and Irvin L. Suppression of lymphocyte activity after acute morphine administration appears to be glucocorticoid independent. Prog. Clin. Biol. Res. 325 (1990) 273-282
3. Bedoui S., Kuhlmann S., Nave H., Drube J., Pabst R., and von H.S. Differential effects of neuropeptide Y (NPY) on leukocyte subsets in the blood: mobilization of B-1-like B-lymphocytes and activated monocytes. J. Neuroimmunol. 117 (2001) 125-132
4. Bedoui S., Lechner S., Gebhardt T., Nave H., Beck-Sickinger A.G., Straub R.H., Pabst R., and von H.S. NPY modulates epinephrine-induced leukocytosis via Y-1 and Y-5 receptor activation in vivo: sympathetic co-transmission during leukocyte mobilization. J. Neuroimmunol. 132 (2002) 25-33
5. Carr D.J., Mayo S., Gebhardt B.M., and Porter J. Central alpha-adrenergic involvement in morphine-mediated suppression of splenic natural killer activity. J. Neuroimmunol. 53 (1994) 53-63
6. Doods H.N., Wieland H.A., Engel W., Eberlein W., Willim K.D., Entzeroth M., Wienen W., and Rudolf K. BIBP 3226, the first selective neuropeptide Y1 receptor antagonist: a review of its pharmacological properties. Regul. Pept. 65 (1996) 71-77
7. Fecho K., and Lysle D.T. Phenotypic analysis of splenocyte subsets following acute morphine treatment in the rat. Cell. Immunol. 195 (1999) 137-146
8. Fecho K., Dykstra L.A., and Lysle D.T. Evidence for beta-adrenergic-receptor involvement in the immunomodulatory effects of morphine. J. Pharmacol. Exp. Ther. 265 (1993) 1079-1087
9. Fecho K., Maslonek K.A., Dykstra L.A., and Lysle D.T. Assessment of the involvement of central nervous system and peripheral opioid receptors in the immunomodulatory effects of acute morphine treatment in rats. J. Pharmacol. Exp. Ther. 276 (1996) 626-636
10. Fecho K., Maslonek K.A., Dykstra L.A., and Lysle D.T. Evidence for sympathetic and adrenal involvement in the immunomodulatory effects of acute morphine treatment in rats. J. Pharmacol. Exp. Ther. 277 (1996) 633-645
11. Felten S.Y., and Olschowka J. Noradrenergic sympathetic innervation of the spleen: II. Tyrosine hydroxylase (TH)-positive nerve terminals form synapticlike contacts on lymphocytes in the splenic white pulp. J. Neurosci. Res. 18 (1987) 37-48
12. Felten D.L., Felten S.Y., Carlson S.L., Olschowka J.A., and Livnat S. Noradrenergic and peptidergic innervation of lymphoid tissue. J. Immunol. 135 (1985) 755s-765s
13. Freier D.O., and Fuchs B.A. A mechanism of action for morphine-induced immunosuppression: corticosterone mediates morphine-induced suppression of natural killer cell activity. J. Pharmacol. Exp. Ther. 270 (1994) 1127-1133
14. Friedman E.M., Irwin M.R., and Nonogaki K. Neuropeptide Y inhibits in vivo specific antibody production in rats. Brain Behav. Immun. 9 (1995) 182-189
15. Harris P.D., and Garret R. Susceptibility of addicts to infection and neoplasia. N. Engl. J. Med. 287 (1972) 310
16. Hernandez M.C., Flores L.R., and Bayer B.M. Immunosuppression by morphine is mediated by central pathways. J. Pharmacol. Exp. Ther. 267 (1993) 1336-1341
17. Hussey H.H., and Katz S. Infections resulting from narcotic addiction: report of 102 cases. Am. J. Med. 9 (1950) 186-193
18. Irwin M., Hauger R.L., Jones L., Provencio M., and Britton K.T. Sympathetic nervous system mediates central corticotropin-releasing factor induced suppression of natural killer cytotoxicity. J. Pharmacol. Exp. Ther. 255 (1990) 101-107
19. Irwin M., Brown M., Patterson T., Hauger R., Mascovich A., and Grant I. Neuropeptide Y and natural killer cell activity: findings in depression and Alzheimer caregiver stress. FASEB J. 5 (1991) 3100-3107
20. Lewis J.W., Shavit Y., Terman G.W., Gale R.P., and Liebeskind J.C. Stress and morphine affect survival of rats challenged with a mammary ascites tumor (MAT 13762B). Nat. Immun. Cell Growth Regul. 3 (1983) 43-50
21. Liang-Suo J., Gomez-Flores R., and Weber R.J. Immunosuppression induced by central action of morphine is not blocked by mifepristone (RU 486). Life Sci. 71 (2002) 2595-2602
22. Louria D.B., Hensle T., and Rose J. The major medical complications of heroin addiction. Ann. Intern. Med. 67 (1967) 1-22
23. Luttgens W.F. Endocarditis in "main line" opium addicts. Arch. Intern. Med. 83 (1949) 653-664
24. Lysle D.T., Hoffman K.E., and Dykstra L.A. Evidence for the involvement of the caudal region of the periaqueductal gray in a subset of morphine-induced alterations of immune status. J. Pharmacol. Exp. Ther. 277 (1996) 1533-1540
25. Madden J.J., Donahoe R.M., Zwemer-Collins J., Shafer D.A., and Falek A. Binding of naloxone to human T lymphocytes. Biochem. Pharmacol. 36 (1987) 4103-4109
26. Medina S., Del R.M., Hernanz A., and De la F.M. Age-related changes in the neuropeptide Y effects on murine lymphoproliferation and interleukin-2 production. Peptides 21 (2000) 1403-1409
27. Mormede P., Castagne V., Rivet J.M., Gaillard R., and Corder R. Involvement of neuropeptide Y in neuroendocrine stress responses. Central and peripheral studies. J. Neural Transm., Suppl. 29 (1990) 65-75
28. Nair M.P., Schwartz S.A., Wu K., and Kronfol Z. Effect of neuropeptide Y on natural killer activity of normal human lymphocytes. Brain Behav. Immun. 7 (1993) 70-78
29. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986)
30. 125I]NPY binding sites. J. Neuroimmunol. 54 (1994) 81-86
31. Pontieri F.E., Tanda G., and Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 12304-12308
32. Pross H.F., and Maroun J.A. The standardization of Nk cell assays for use in studies of biological response modifiers. J. Immunol. Methods 68 (1984) 235-249
33. Romano T.A., Felten S.Y., Felten D.L., and Olschowka J.A. Neuropeptide-Y innervation of the rat spleen: another potential immunomodulatory neuropeptide. Brain Behav. Immun. 5 (1991) 116-131
34. Saurer T.B., Carrigan K.A., Ijames S.G., and Lysle D.T. Suppression of natural killer cell activity by morphine is mediated by the nucleus accumbens shell. J. Neuroimmunol. 173 (2006) 3-11
35. Shavit Y., Depaulis A., Martin F.C., Terman G.W., Pechnick R.N., Zane C.J., Gale R.P., and Liebeskind J.C. Involvement of brain opiate receptors in the immune-suppressive effect of morphine. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 7114-7117
36. Takamoto T., Hori Y., Koga Y., Toshima H., Hara A., and Yokoyama M.M. Norepinephrine inhibits human natural killer cell activity in vitro. Int. J. Neurosci. 58 (1991) 127-131
37. Tubaro E., Borelli G., Croce C., Cavallo G., and Santiangeli C. Effect of morphine on resistance to infection. J. Infect. Dis. 148 (1983) 656-666
38. von Horsten S., Ballof J., Helfritz F., Nave H., Meyer D., Schmidt R.E., Stalp M., Klemm A., Tschernig T., and Pabst R. Modulation of innate immune functions by intracerebroventricularly applied neuropeptide Y: dose and time dependent effects. Life Sci. 63 (1998) 909-922
39. Weber R.J., and Pert A. The periaqueductal gray-matter mediates opiate-induced immunosuppression. Science 245 (1989) 188-190
40. Wybran J., Appelboom T., Famaey J.P., and Govaerts A. Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes. J. Immunol. 123 (1979) 1068-1070
41. Yeager M.P., Colacchio T.A., Yu C.T., Hildebrandt L., Howell A.L., Weiss J., and Guyre P.M. Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 83 (1995) 500-508